First Japanese Institution to Utilize SOPHiA GENETICS’ Myeloid Plus Solution

BOSTON, United States, LAUSANNE, Switzerland, and HIROSHIMA, Japan – February 22, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan, to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders. Hiroshima University is home to one of …

First Japanese Institution to Utilize SOPHiA GENETICS’ Myeloid Plus Solution Read More »

transmutex - 4seeventures

Media Coverage Update

It has been been quite a media coverage ride in the last few weeks ! One article featuring our Scientific Director, Dr. Federico Carminati, was published on Swiss Info and translated in 7 other languages ! Free Access, Links below. “”When a Nobel Prize winner asks you to work with him, it’s hard to say …

Media Coverage Update Read More »

CYBERSECURITY FOR ENTERPRISE BLOCKCHAIN SOLUTIONS

More and more enterprises analyze and deploy blockchain and distributed ledger technology (DLT) based solutions. Enabling the interconnection between network participants without depending on a central technology intermediary is seen as a key advantage for Enterprise Blockchain Solutions. However, with the new decentralized enterprise solutions, the cybersecurity management requirements are changing too. Public and a …

CYBERSECURITY FOR ENTERPRISE BLOCKCHAIN SOLUTIONS Read More »

HAYA Therapeutics Establishes U.S. Location

HAYA closes US$5M seed extension led by Humboldt Fund to advance the development of its anti-fibrotic lead program targeting Wisper, a cardiac long non-coding RNA LAUSANNE, Switzerland & SAN DIEGO–(BUSINESS WIRE)–HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), today announced that the company has established a …

HAYA Therapeutics Establishes U.S. Location Read More »

Dexter Series E: $90M to Make Sense of Robotic Surgery

Distalmotion, Revival Healthcare Capital and 415 CAPITAL announce the closing of a USD 90 million Series E financing round to accelerate the adoption of Distalmotion’s surgical robot Dexter. The investment follows Dexter’s successful initial clinical use and supports Distalmotion’s international commercial scaling. READ MORE

Institut Paoli Calmettes Extends Partnership with SOPHiA GENETICS

BOSTON, LAUSANNE, BORDEAUX, and MARSEILLE – FEBRUARY 1, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, have announced, in conjunction with Assises de Génétique, an extension of their partnership with Institut Paoli Calmettes (IPC), one of the 18 French Comprehensive Cancer Centers (CLCC), to further support the implementation, automatization, and accreditation of solid tumor …

Institut Paoli Calmettes Extends Partnership with SOPHiA GENETICS Read More »

SOPHiA GENETICS Appoints Ken Freedman as Chief Revenue Officer

BOSTON and LAUSANNE, Switzerland, January 26, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that democratizes data-driven medicine, today announced that Ken Freedman has been appointed Chief Revenue Officer. With a background in serving some of the most innovative providers of technology to the world-wide media space, Ken brings more than 25 …

SOPHiA GENETICS Appoints Ken Freedman as Chief Revenue Officer Read More »